K

Karolinska Development AB
STO:KDEV

Watchlist Manager
Karolinska Development AB
STO:KDEV
Watchlist
Price: 1.21 SEK 0.17% Market Closed
Market Cap: 323.4m SEK
Have any thoughts about
Karolinska Development AB?
Write Note
Section:
 

Relative Value

The Relative Value of one KDEV stock under the Base Case scenario is 0.06 SEK. Compared to the current market price of 1.21 SEK, Karolinska Development AB is Overvalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KDEV Relative Value
Base Case
0.06 SEK
Overvaluation 95%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

171.6
P/S
P/S
Price to Sales
171.6
vs History
69
vs Industry
3
Median 3Y
218.2
Median 5Y
208.4
Industry
2.6
Forward
160
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
34
Median 3Y
-4.1
Median 5Y
2.1
Industry
22.3
Forward
-12
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15
Industry
17.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-14.7
Industry
24.8
More Details
0.3
P/B
P/B
Price to Book Value
0.3
vs History
98
vs Industry
78
Median 3Y
0.4
Median 5Y
0.5
Industry
2.1
More Details
140.2
EV/S
EV/S
Enterprise Value to Sales
140.2
vs History
57
vs Industry
3
Median 3Y
171.4
Median 5Y
152.9
Industry
2.7
Forward
130.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-13.5
Industry
13.4
Forward
-8.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-19.6
Median 5Y
-13.5
Industry
16.8
Forward
-8.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.4
Industry
15.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.4
Industry
18.5
More Details
0.2
EV/IC
EV/IC
Enterprise Value to IC
0.2
vs History
95
vs Industry
81
Median 3Y
0.3
Median 5Y
0.4
Industry
1.9
More Details

Multiples Across Competitors

KDEV Competitors Multiples
Karolinska Development AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Karolinska Development AB
STO:KDEV
326.5m SEK 171.6 -57.8 -12.1 -11.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
793.7B USD 20.3 107.4 54.1 60.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.1 37.5 25 28.7
US
Johnson & Johnson
NYSE:JNJ
385.5B USD 4.4 26.2 12.7 16.5
US
Merck & Co Inc
NYSE:MRK
260.6B USD 4.2 18.9 12.9 15.8
CH
Roche Holding AG
SIX:ROG
213.6B CHF 3.6 18.6 10.4 12.4
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 4.5 34.3 169.8 254.4
CH
Novartis AG
SIX:NOVN
183.5B CHF 4.3 13.1 10.4 15.4
US
Pfizer Inc
NYSE:PFE
160.4B USD 2.7 37.7 11 16.7
P/E Multiple
Earnings Growth
SE
K
Karolinska Development AB
STO:KDEV
Average P/E: 36.7
Negative Multiple: -57.8 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
107.4
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.2
-22%
US
Merck & Co Inc
NYSE:MRK
18.9
7 426%
CH
Roche Holding AG
SIX:ROG
18.6
30%
UK
AstraZeneca PLC
LSE:AZN
34.3
175%
CH
Novartis AG
SIX:NOVN
13.1
19%
US
Pfizer Inc
NYSE:PFE
37.7
712%

See Also

Summary
KDEV intrinsic value, competitors valuation, and company profile.
DCF Valuation
KDEV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KDEV stock valuation using valuation multiples.
Wall Street Estimates
KDEV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KDEV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 193,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.